Bruker (BRKR)
(Delayed Data from NSDQ)
$80.97 USD
+0.38 (0.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $80.94 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BRKR 80.97 +0.38(0.47%)
Will BRKR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BRKR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRKR
Earnings Preview: Bruker (BRKR) Q1 Earnings Expected to Decline
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
BRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
Why Is Bruker (BRKR) Up 15.7% Since Last Earnings Report?
Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?
Other News for BRKR
Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast
Bruker Corporation: An Aggressive Acquisition Strategy
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Bruker (BRKR) and Gilead Sciences (GILD)
Bruker to Acquire the NanoString Business in an Asset Deal